Cereno Scientific is developing a new preventive drug that normalizes the body’s own defence system against blood clots – to be used on the global market for the treatment of complications resulting from thrombosis-related cardiovascular diseases.
Cereno Scientific’s vision is to develop a new drug for the prevention of blood clots based on the body’s own intelligent clot-busting system.
The benefit of this new therapy compared to all current preventative antithrombotic therapy is expected to be an improved balance between blood clot prevention and side effects. This gives patients at risk for blood clots opportunities for a better preventive drug treatment. More effective treatment creates opportunities to reduce the suffering of large groups of patients leading to significant health and economic benefits.
Showcase to 300+ investors and pharma at our 5th flagship LSX World Congress.
Plus save £500 before 14th December!
LSX, formerly Biotech and Money, is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.